Pharmaceutical Market Research: Reshaping the Industry
Executive Summary
Objective
This pharmaceutical market research report, prepared by Desk Research Group, consolidates insights from global pharmaceutical industry databases, regulatory publications, and financial analyses to deliver an integrated market perspective. The analysis explores growth drivers, regulatory considerations, technological innovation, consumer demand, and the competitive environment. The objective is to deliver actionable intelligence that enables pharmaceutical firms, investors, and policymakers to anticipate industry shifts, allocate resources effectively, and pursue sustainable strategies for long-term growth.
Key Findings
The pharmaceutical industry is experiencing structural transformation. Biologics and biosimilars are capturing increasing market share, while small molecule drugs, once dominant, are facing stagnation. Regulatory frameworks in Canada and the United Kingdom continue to prioritise patient safety and cost-effectiveness, with growing emphasis on real-world evidence and health technology assessments. Technological advancements, particularly in artificial intelligence for drug discovery and digitalisation of clinical trials, are accelerating development timelines but require significant upfront investment. The industry faces intensifying cost pressures as payers demand demonstrable value and governments scrutinise pricing more closely.
Recommendations
1. Prioritise diversified portfolios that combine high-margin innovative therapies with cost-competitive generics and biosimilars.
2. Engage proactively with regulators and payers to align product positioning with reimbursement frameworks.
3. Invest in digital and data capabilities to improve trial efficiency and enhance post-market surveillance.
4. Strengthen supply chain resilience to mitigate future shocks, including geopolitical tensions and raw material shortages.
Table of Contents
Findings and Insights
Forecast to surpass USD 2.1 trillion by 2030
The global pharmaceutical market exceeded USD 1.5 trillion in 2023 and is forecast to surpass USD 2.1 trillion by 2030. Chronic diseases such as diabetes, cardiovascular disease, and cancer are primary growth drivers. The prevalence of rare diseases has also created opportunities for niche therapies, supported by regulatory incentives such as orphan drug designations.
The COVID-19 pandemic reshaped industry dynamics by accelerating vaccine development and demonstrating the viability of public–private partnerships. It also highlighted vulnerabilities in global supply chains, particularly in the dependence on active pharmaceutical ingredient (API) production in Asia.
Pharmacovigilance and equitable access
Canada: Health Canada regulates under the Food and Drugs Act and the Patented Medicine Prices Review Board (PMPRB) enforces pricing limits. There is strong emphasis on pharmacovigilance and equitable access across provinces. Canada’s universal healthcare model magnifies the role of reimbursement decisions in determining market viability.
United Kingdom: Post-Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) has autonomy from the European Medicines Agency (EMA). The National Institute for Health and Care Excellence (NICE) continues to play a pivotal role in health technology assessments, where cost-effectiveness thresholds influence adoption. Market entry in the United Kingdom often requires clear demonstration of quality-adjusted life year (QALY) benefits relative to price.
Technogical Advancements
Artificial intelligence and machine learning are compressing discovery timelines from years to months. Digitalisation of trials, including decentralised models, is expanding patient recruitment and reducing dropout rates. Manufacturing innovations such as continuous bioprocessing are improving scalability, particularly for biologics. However, these advancements increase dependence on digital infrastructure, raising cybersecurity concerns.
Target Market Analysis
Demographics:
Developed Markets: Ageing populations in Canada, the United Kingdom, and Europe drive demand for chronic disease management, oncology therapies, and neurological treatments.
Emerging Markets: Younger populations create growth potential for vaccines, infectious disease treatments, and lower-cost generics.
Psychographics:
Patients are increasingly informed and demand transparency regarding efficacy, side effects, and cost. There is rising resistance to high-priced therapies without clear evidence of value. Physicians and healthcare providers are embracing personalised medicine where feasible, but reimbursement remains the gatekeeper.
Needs Assessment:
• Affordable therapies for chronic and rare diseases.
• Faster access to innovative treatments, balanced against regulatory scrutiny.
• Greater diversity in clinical trial populations to ensure equity and efficacy across demographics.
Competitive Landscape
Key Competitors:
Multinational leaders include Pfizer, Roche, Novartis, Johnson & Johnson, and Merck. In generics, firms such as Teva and Sandoz remain competitive. Contract research organisations (CROs) like IQVIA and Parexel play vital roles in clinical development. In Canada, firms such as Apotex maintain a strong domestic footprint, while in the United Kingdom, companies like GSK remain influential in both domestic and global markets.
Strengths
Strengths: Deep R&D pipelines, global networks, and access to capital.
Weaknesses
Weaknesses: Patent cliffs, escalating development costs, and regulatory hurdles.
Opportunities
Opportunities: Growth of biosimilars, expansion into emerging markets, and partnerships with digital health companies.
Threats
Threats: Pricing pressures from payers, supply chain vulnerabilities, and increasing regulatory scrutiny on marketing practices.
Competitive Strategies:
Leaders are adopting hybrid strategies: developing innovative biologics while ensuring stable generics revenue streams. Strategic alliances with biotechnology start-ups and digital health providers are common. Many firms are investing in outcome-based pricing models to align with payer expectations.
Market Trends and Opportunities
Consumer Behavior:
Patients are more active in decision-making, with digital platforms enabling access to comparative drug information. Affordability remains central, driving strong uptake of generics where available.
Innovation:
Biologics and biosimilars now account for nearly one-third of pharmaceutical revenue. Messenger RNA (mRNA) platforms, initially developed for COVID-19, are expanding into oncology and metabolic disorders.
Growth Areas:
Short-term: Generics expansion and biosimilars in oncology and immunology.
Medium-term: Personalised therapies for oncology and rare diseases, supported by companion diagnostics.
Long-term: Gene editing, regenerative medicine, and digital therapeutics.
Research Methodology
Data Collection
Insights are based on secondary research, including published interviews with executives, industry white papers, and government data. The primary data included structured interviews with pharmaceutical executives, regulators, clinicians, and patient advocacy groups. Secondary data sources comprised industry databases, financial reports, government publications, and peer-reviewed literature.
Sampling
The sample included executives from 50 multinational and regional firms, clinicians from major therapeutic areas, and patients across Canada and the United Kingdom.
Analysis Techniques
Quantitative forecasting applied compound annual growth rate models, while qualitative thematic analysis identified recurrent themes in expert interviews. Scenario planning was applied to regulatory and technological adoption.
Finding and Insights
Quantitative Data:
- Global pharmaceutical market compound annual growth rate projected at 5.4 percent through 2030.
- Biologics projected to account for 35 percent of revenues by 2030.
- In Canada and the United Kingdom, generics represent over 70 percent of prescriptions but less than 25 percent of overall spend due to biologic costs.
Qualitative Insights
Executives underscored the urgency of diversifying pipelines to avoid over-reliance on single blockbuster drugs. Regulators in Canada and the United Kingdom stressed the importance of affordability, warning that pricing misalignment may lead to restricted access.
Interpretation
The industry’s trajectory depends on its ability to reconcile innovation with affordability. Firms that adapt pricing and demonstrate real-world value will capture competitive advantage.
Recommendations
Strategic Actions:
- Strengthen investment in biologics, biosimilars, and advanced therapies.
- Build partnerships with digital health companies for clinical trial efficiency.
- Engage payers early to develop acceptable pricing and reimbursement frameworks.
Implementation Timeline:
0–2 years: Expand biosimilars portfolio; adopt digital trial infrastructure.
2–3 years: Launch personalised oncology and rare disease therapies in line with regulatory approvals.
5+ years: Establish leadership in gene therapies and advanced regenerative medicine.
Resource Allocation:
A minimum of 20–25 percent of R&D budgets should be dedicated to biologics and digitalisation. Strategic partnerships with biotechnology start-ups will offset risk.
Conclusion
Summary
The pharmaceutical sector is at a pivotal juncture, with biologics, biosimilars, and advanced therapies reshaping the landscape. Regulatory scrutiny on affordability is intensifying, particularly in Canada and the United Kingdom. Digital transformation will redefine research, development, and patient engagement.
Future Outlook
2–3 years: Biosimilars become mainstream in oncology and immunology. Decentralised clinical trials gain broader adoption, improving access and diversity. Regulatory pathways in Canada and the United Kingdom continue to tighten cost-effectiveness criteria.
5+ years: Advanced therapies such as gene editing and regenerative medicine move from niche to broader adoption, contingent on pricing innovation. Artificial intelligence in drug discovery becomes standard practice, compressing development timelines. By 2030, outcome-based pricing models will dominate reimbursement negotiations, redefining value in the pharmaceutical market.
Assumptions underpinning this outlook include continued government pressure on pricing, accelerated patient demand for access to innovative therapies, and sustained technological progress in artificial intelligence and genomics.
Appendices
Glossary:
Biologics
Drugs made from living cells (e.g., antibodies, gene therapies). Complex, powerful, and expensive.
Biosimilars
Near-copies of biologics. Not exact clones, but proven to work just as well—like the sequel no one asked for but works anyway.
Real-World Evidence (RWE)
Data on how drugs perform outside clinical trials, drawn from records, claims, and registries. It’s medicine in the wild.
Quality-Adjusted Life Year (QALY)
A metric: 1 year of perfect health = 1 QALY. Used to judge if a drug’s benefits justify its cost.
References:
Health Canada
Canada’s regulatory authority—approves drugs, monitors safety, and sets national standards for pharma products.
World Health Organisation (WHO)
Sets global health policies, essential medicine lists, and drug safety guidance.
IQVIA Institute
Publishes data on drug spending, uptake, pipelines, and trends.
Deloitte Life Sciences Reports
Consulting analyses on pharma strategy, R&D productivity, pricing, and future market dynamics.
